Example: Heart Attack

Clinical Trials on Richter Syndrome

Total 55 results

NCT03054896

Recruiting

A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome

Conditions: Richter Syndrome
NCT03619512

Recruiting

Genomic and Proteomic Study of Richter Syndrome (CGPSR)

Conditions: Richter Syndrome
NCT03899337

Not yet recruiting

A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome

Conditions: Richter Syndrome
NCT03145480

Terminated

Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients

Conditions: Richter Syndrome
NCT01171378

Completed

Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter's Syndrome

Conditions: Richter's Syndrome
NCT03931642

Recruiting

BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation

Conditions: Richter Syndrome
NCT03113695

Recruiting

Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome

Conditions: Richter's Syndrome; CLL
NCT02576990

Completed

Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)

Conditions: Mediastinal Large B-cell Lymphoma; Richter Syndrome
NCT04679012

Not yet recruiting

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

Conditions: Richter Syndrome; Chronic Lymphocytic Leukemia
NCT02535286

Active, not recruiting

Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation

Conditions: Chronic Lymphocytic Leukemia; Richter Syndrome
NCT03534323

Recruiting

Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

Conditions: Chronic Lymphocytic Leukemia; Richter Syndrome
NCT02138786

Terminated

Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation

Conditions: Richter's Transformation
NCT02378038

Terminated

PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)

Conditions: Richter's Transformation
NCT04271956

Recruiting

Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter Transformation

Conditions: Richter Transformation
NCT03121534

Active, not recruiting

Study of Blinatumomab in Richter Transformation

Conditions: Hematopoietic/Lymphoid Cancer; Richter's Transformation
NCT03153514

Terminated

Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation

Conditions: Chronic Lymphocytic Leukemia; Richter's Transformation
NCT00472849

Completed

Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias

Conditions: Richter's Transformation; Leukemia
NCT03892044

Recruiting

Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

Conditions: Chronic Lymphocytic Leukemia; Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Richter Syndrome; Small Lymphocytic Lymphoma; Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma; Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma; Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma
NCT02846623

Recruiting

Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

Conditions: Chronic Lymphocytic Leukemia; Recurrent Transformed Chronic Lymphocytic Leukemia; Refractory Transformed Chronic Lymphocytic Leukemia; Richter Syndrome; Small Lymphocytic Lymphoma
NCT00304005

Completed

VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders

Conditions: Leukemia; Lymphoma
NCT04781855

Not yet recruiting

Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

Conditions: Hematopoietic and Lymphoid Cell Neoplasm; Recurrent Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma; Richter Syndrome
NCT03205046

Terminated

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

Conditions: DLBCL; Richter Syndrome
NCT02029443

Unknown status

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Richter's Syndrome; Prolymphocytic Leukemia
NCT03884998

Recruiting

Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma

Conditions: Chronic Lymphocytic Leukemia; Richter Syndrome; Diffuse Large B Cell Lymphoma; Follicular Lymphoma; Indolent Non-hodgkin Lymphoma; Loss of Chromosome 17p; Lymphoplasmacytic Lymphoma; Marginal Zone Lymphoma; TP53 Gene Mutation
NCT00452374

Completed

Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL

Conditions: Leukemia